MedPage Today on MSN9d
TYK2 Inhibitor Scores Two Wins Outside Plaque Psoriasis
The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Hosted on MSN1mon
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
"Our results indicate that interferon-alpha-1 and interferon-alpha-2 can recruit different JAK members with unexpected promiscuity; however, optimal signaling activity requires JAK1 and TYK2." ...
MedPage Today on MSN5d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor
ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Nasdaq1mon
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the ...
Investing19d
Alumis to present new data on multiple sclerosis therapy
The presentations will reveal findings on A-005's potent inhibition of TYK2 signaling in immune and CNS resident cells, which could play a role in treating neuroinflammatory diseases. Jörn Drappa ...
Healio10d
Oral TYK2 inhibitor has ‘outstanding efficiency’ in plaque psoriasis
A once-daily TYK2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter. Image: Adobe Stock. The primary endpoint was the ...
Morningstar1mon
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
“These results further support the role of Sotyktu, the first TYK2 inhibitor available for patients living with moderate-to-severe plaque psoriasis, as a potential oral standard of care.